Phillips T L, Fu K K
Cancer. 1976 Feb;37(2 Suppl):1186-1200. doi: 10.1002/1097-0142(197602)37:2+<1186::aid-cncr2820370830>3.0.co;2-v.
In order to determine the modification of radiation effects on critical normal tissues which occurs with combinations of radiation and cancer chemotherapy, a review of laboratory and clinical data has been carried out. Information on 10 different normal tissues is available. It is clear that the antibiotic cancer chemotherapeutic agents are the most likely to enhance radiation injury, with increased levels reported in all tissues except the central nervous system. The second most common type of injury with combination therapy appears to occur with drugs causing injury to the normal tissue on their own, such as adriamycin in the heart and methotrexate in the central nervous system. Quantification of the dose-effect factor is only available on a limited number of tissues, and, primarily, in experimental animals. From these limited data, it is clear that dose-effect factors between 1.1 and 1.8 are seen, indicating that radiation doses must be reduced by 10-80% for the same level of injury when combined with chemotherapy. The augmentation of radiation damage by cancer chemotherapeutic agents is a serious problem in a wide range of tissues, but a problem which can be dealt with by accurate knowledge as to the dose-effect factor and appropriate modification of the radiation treatment.
为了确定放射与癌症化疗联合使用时对关键正常组织辐射效应的改变,已对实验室和临床数据进行了综述。现有关于10种不同正常组织的信息。显然,抗生素类癌症化疗药物最有可能增强辐射损伤,除中枢神经系统外,所有组织中均报告有损伤水平增加。联合治疗中第二常见的损伤类型似乎发生在自身就会对正常组织造成损伤的药物上,如心脏中的阿霉素和中枢神经系统中的甲氨蝶呤。剂量效应因子的量化仅在有限数量的组织中可用,且主要是在实验动物中。从这些有限的数据来看,很明显剂量效应因子在1.1至1.8之间,这表明与化疗联合使用时,为达到相同的损伤水平,辐射剂量必须降低10% - 80%。癌症化疗药物对辐射损伤的增强在广泛的组织中是一个严重问题,但通过准确了解剂量效应因子并适当调整放射治疗,这个问题是可以解决的。